Crohn’s Disease in Children: Increase in cases of Crohn’s disease in children under 5 years old

Short on time? Here is the essential ✨
Increase in cases among children under 5 years old: trend confirmed by several international registries 📈.
Early diagnosis essential to protect growth and avoid complications 🧭.
Digestive symptoms sometimes subtle, but vigilance on fatigue and growth retardation 🧒.
Personalized pediatric treatment: exclusive enteral nutrition, corticosteroids, biotherapies 💊.
Intestinal inflammation monitored by fecal calprotectin to guide therapeutic intensification 🔬.
Early environment: protective biodiversity, intensive agricultural lands associated with increased risk 🌳🌾.

Crohn’s Disease is progressing among Children, including the very young. Pediatric teams report an increase in cases among children under 5 years old, an age at which manifestations can be atypical. Rapid recognition of digestive symptoms and extra-digestive signs then becomes crucial to preserve child health and growth. This development, documented by national studies and international analyses, requires adapting clinical reflexes and care pathways.

In this context, intestinal inflammation must be tracked early, with an early diagnosis based on robust markers (CRP, erythrocyte sedimentation rate, fecal calprotectin) and targeted imaging. Pediatric treatment has evolved: exclusive enteral nutrition, short-course corticosteroids, immunomodulators, and anti-TNF biotherapies have redefined standards. Meanwhile, the environment of the early years of life is studied: some factors appear protective, others increase risk. Understand, detect, act early: this is the dynamic to initiate to enable children to grow up with ambition despite a chronic disease.

Increase in Crohn’s disease cases among children under 5 years old: data, signals, and challenges

This is no longer anecdotal: the increase in cases of Crohn’s Disease among children under 5 years old is reported in several countries. Pediatric registries have noted a rise over the last two decades, consistent with global analyses published in leading journals. In Canada, for example, a marked increase in chronic inflammatory bowel diseases among the young has been described, confirming an underlying phenomenon.

In France, IBD affects approximately 100,000 to 150,000 people, with a peak in adolescents and young adults. However, pediatric forms account for nearly 10% of cases, and clinicians observe more newly diagnosed children. This increase does not mean an explosion among infants, but signals increased vigilance for the very young.

Epidemiological trend and clinical reality

Hospital teams see a flow of preschool-aged children presenting sometimes misleading signs. In pediatric gastroenterology departments, the monthly arrival of several new cases is no longer exceptional. This does not reflect only improved screening: risk factors accumulate, creating a favorable environment in the youngest.

Pediatric forms often appear more severe and more progressive. They threaten growth and puberty, hence the urgency of early detection of intestinal inflammation. Postponing investigation exposes the child to growth delays sometimes difficult to catch up.

What plausible explanations?

Genetic predisposition exists: 10 to 15% of patients have first-degree family history. Dozens of susceptibility genes have been identified, including NOD2/CARD15, which significantly multiplies risk. However, the recent rise is also explained by the environment. Among the leads: passive smoking, early microbiota changes, refrigeration, and exposure to certain infectious agents such as Yersinia.

National cohorts have highlighted the role of environment at the very beginning of life: intensive use of agricultural lands would increase risk, while biodiversity and green spaces would exert a protective effect. This ecological view complements the clinical approach and encourages urban policies favorable to health.

Why this changes everything for child health

For a child under 5 years old, any diagnostic delay impacts life trajectory. Growing, learning, creating bonds: all depend on digestive comfort and sufficient alimentation. Early control of intestinal inflammation avoids repeated hospitalizations and supports the child’s confidence.

Parents and caregivers benefit from maintaining a shared “alert thread”: if symptoms persist, a structured approach is necessary. A young patient progressing well academically and physically at 5 years old is often a diagnosis made at the right time. This is the key point to retain.

Early detection of digestive and extra-digestive symptoms in toddlers

Contrary to common belief, Crohn’s Disease in toddlers is not limited to obvious abdominal pain. Digestive symptoms can be intermittent and go unnoticed. It is often fatigue and a growth slowdown that trigger the first alarm. A less playful child, who eats little, loses weight or stops growing, deserves careful evaluation.

Anal manifestations (fissures, small fistulas, perineal lesions) point to inflammatory involvement. Sometimes diarrhea is subtle or even absent. A picture without fever with capricious appetite and diffuse pain should lead to investigation rather than waiting.

Warning signs to watch for without delay

• 🍽️ Persistent loss of appetite and refusal of usually appreciated textures.
• 📉 Weight or height slowdown, “breaking” curve on the health booklet.
• 🚽 Frequent stools, sometimes mucus or bloody, or alternating constipation/diarrhea.
• 🔴 Painful or recurrent ano-perineal lesions.
• 😴 Persistent fatigue, irritability, longer naps than usual.
• 🦵 Unexplained joint pain, occasional limping.
• 🟣 Painful skin nodules (erythema nodosum) or recurrent mouth ulcers.

Let’s illustrate with Mila, 4 years old. She has recurring fissures, little abdominal pain, and poor appetite. Her height curve flattens over two successive consultations. The suspicion builds because the elements add up. The message is clear: one must think Crohn’s even without a “typical” picture.

The emotional atmosphere at home also matters. Night awakenings, new irritability, tears at the table sometimes reflect discomfort. Parents feel helpless. However, a simple plan with the pediatrician – close follow-up, food diary, pain tracking, photo of perineal lesions if needed – speeds up the decision to investigate.

What caregivers recommend daily

A period of three to four weeks of active observation rarely suffices if signs persist. Pediatricians then propose blood tests and fecal calprotectin. This non-invasive tool detects intestinal inflammation and helps sort situations. The earlier the alert is raised, the more the early diagnosis protects child health.

In practice, speaking early about symptoms and objectifying the situation saves precious time. Every week counts for growth. Detecting is already treating.

Early diagnosis and adapted care pathways in pediatrics

Early diagnosis of Crohn’s Disease in children relies on a body of evidence. Biology, imaging, and endoscopy complement each other. The objective is to quickly establish proof of active intestinal inflammation and its location, to align pediatric treatment on a clear course.

Initial assessment: biology and inflammation markers

A standard panel is performed: CRP, blood count, deficiencies (iron, vitamins), albumin, and erythrocyte sedimentation rate. In pediatrics, an ESR above 10 draws attention. Fecal calprotectin is decisive: elevated, it signals digestive inflammation and guides morphological exams.

This biomarker also guides follow-up. A secondary elevation during remission requires discussion of therapeutic intensification. It is a cornerstone of “treat-to-target” in pediatric age.

Targeted imaging and endoscopy

Entero-MRI visualizes the small intestine, often affected in Crohn’s Disease. It maps inflamed segments, stenoses, fistulas. Colonoscopy with ileoscopy and multiple biopsies confirms the disease via typical lesions. The presence of epithelioid and giant cell granulomas, when present, strongly supports diagnosis.

These explorations do not contradict clinical evaluation. They extend it. A simple but essential examination of the anal area detects often telling lesions in young children.

Differentiating to treat correctly

Infectious, allergic, or functional presentations must be excluded. Vigilance remains in infants where rare monogenic forms require specialized analysis. In most cases, however, the biological-imaging-endoscopy algorithm suffices to make the diagnosis and initiate management without delay.

Informing families, structuring the schedule, reassuring the child: these are therapeutic acts in their own right. A smooth pathway alleviates fears and promotes adherence.

Education at the time of examinations changes the child’s experience. Simple words, a security blanket, acclimation time: these details matter. Because the care alliance begins well before the first treatment, it conditions success.

Pediatric treatment of Crohn’s disease: enteral nutrition, corticosteroids, and biotherapies

Crohn’s Disease is a chronic disease that can be controlled, and a child can flourish when intestinal inflammation is mastered. Pediatric treatment pursues goals: symptom disappearance, biomarker normalization, mucosal healing, harmonious growth. This course guides therapeutic choices and follow-up intensity.

Exclusive enteral nutrition: soothe and repair

Many teams use exclusive enteral nutrition (EEN) as first-line treatment during flares. Preparations like Modulen are administered over 6 to 8 weeks, orally or enterally if necessary. EEN reduces inflammation, promotes healing, and supports nutritional status without the side effects of corticosteroids.

Success depends on support: planning, taste, intake tips, school support. When EEN is difficult, mixed protocols can be discussed, but adherence remains key.

Corticosteroids and digestive anti-inflammatories

Corticosteroids remain useful to quickly quell a moderate to severe flare. The modern strategy aims for short courses, with planned tapering and maintenance therapy. Digestive anti-inflammatories find their place in limited forms, always under surveillance.

Informing about side effects, managing sleep and appetite, preventing infections: these simple measures secure the course and prevent early relapses.

Immunomodulators, anti-TNF biotherapies, and proactive follow-up

Anti-TNF biotherapies have transformed pediatric management. Hospital infusions or home injections offer durable control. Approximately 15 to 30% of children benefit, depending on disease profile and activity. The goal: prevent structural damage, allow a full and active childhood.

Proactive follow-up relies on fecal calprotectin. A significant elevation during remission necessitates exploration and consideration of therapeutic escalation. This is the “treat-to-target” philosophy: aim for deep remission and adjust without delay.

Daily, the care team also offers up-to-date vaccinations, therapeutic education, and workshops to familiarize children with treatments. Because the child lives in an ecosystem, the whole family learns to coordinate.

Growth, emotions, and school: protecting life trajectory despite chronic disease

Growth is a key indicator. In Crohn’s Disease, intestinal inflammation disrupts appetite and absorption, leading to growth retardation. This reality is not inevitable. Once the disease is controlled, growth curves rebound, puberty normalizes, and energy returns.

Building a safety net for growth

A weighing and measuring schedule every 2 to 3 months helps objectify progress. Dietitians propose adapted intakes, “rich but smart” snacks, and supplements if needed. Meanwhile, monitoring vitamins, iron, and albumin ensures recovery.

Coordinated follow-up – gastroenterologist, pediatrician, nutritionist, psychologist – allows anticipation. Gradual resumption of physical activities nurtures confidence and stimulates appetite. Every victory, even small, counts.

Emotions, siblings, and school: a community around the child

At school, an IHP (individualized health plan) clarifies needs: access to toilets, breaks, storage of nutritional preparations, medical feedback. Reassured teachers become valuable allies. The child regains their place, and the class unites around a clear framework.

Siblings observe, sometimes worry. Explaining with simple words defuses fears. Reassuring routines – familiar menus, evening rituals, playtime – stabilize daily life. Enthusiasm is contagious: celebrating pain-free days motivates treatment adherence.

Hygiene of life and environment: the quiet but real role

Studies on the early environment suggest a protective effect of green spaces and biodiversity. Conversely, strong exposure to intensive agricultural lands could increase the risk of IBD. Without injunctions, this data inspires choices: outings to the park, outdoor play, avoiding passive smoking, diversified diet.

The child remains an adventurer. Offering a setting that reduces inflammation and soothes the stomach gives freedom to run and learn. This is the ambition: let child health flourish despite chronic disease.

“The earlier small signals are heeded, the greater the victories.”

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”What early signs should alert in a child under 5 years old?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Growth slowdown, unusual fatigue, frequent or mucus stools, painful ano-perineal lesions, and persistent loss of appetite. Even without major pain, these signs should lead to a quick assessment.”}},{“@type”:”Question”,”name”:”Is blood testing sufficient to diagnose Crohn’s disease?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. It guides thanks to CRP, erythrocyte sedimentation rate, and blood count. Fecal calprotectin is very useful. Imaging (entero-MRI) and endoscopy with biopsies confirm the disease and localize inflammation.”}},{“@type”:”Question”,”name”:”Does exclusive enteral nutrition replace corticosteroids?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”It can be the first-line induction treatment in children and can induce remission while preserving growth. Corticosteroids remain useful in certain situations, with short and supervised courses.”}},{“@type”:”Question”,”name”:”Are biotherapies common in children?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”They are proposed to about 15 to 30% of children depending on disease activity and extent. They aim for deep remission, with close monitoring via fecal calprotectin and imaging if needed.”}},{“@type”:”Question”,”name”:”What can families do daily?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Document symptoms, maintain an appropriate diet, promote sleep, avoid passive smoking, favor green spaces, and keep regular contact with the pediatric team to quickly adjust treatment.”}}]}

What early signs should alert in a child under 5 years old?

Growth slowdown, unusual fatigue, frequent or mucus stools, painful ano-perineal lesions, and persistent loss of appetite. Even without major pain, these signs should lead to a quick assessment.

Is blood testing sufficient to diagnose Crohn’s disease?

No. It guides thanks to CRP, erythrocyte sedimentation rate, and blood count. Fecal calprotectin is very useful. Imaging (entero-MRI) and endoscopy with biopsies confirm the disease and localize inflammation.

Does exclusive enteral nutrition replace corticosteroids?

It can be the first-line induction treatment in children and can induce remission while preserving growth. Corticosteroids remain useful in certain situations, with short and supervised courses.

Are biotherapies common in children?

They are proposed to about 15 to 30% of children depending on disease activity and extent. They aim for deep remission, with close monitoring via fecal calprotectin and imaging if needed.

What can families do daily?

Document symptoms, maintain an appropriate diet, promote sleep, avoid passive smoking, favor green spaces, and keep regular contact with the pediatric team to quickly adjust treatment.